{"entity":{"id":"nct05475925","kind":"trial","name":"A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas","aka":[],"tldr":"A phase 1/2 trial of DR-01 in peripheral T-cell lymphomas, run by Dren Bio, now recruiting.","summary":"A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas is a phase 1/2 interventional study registered as NCT05475925 by Dren Bio, with 200 participants planned, started 2022-07-13 and due to reach its primary completion in 2026-12. Interventions recorded: DR-01.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05475925","url":"https://clinicaltrials.gov/study/NCT05475925"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["dr-01"],"companies":["dren-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05475925","phase":"1/2","setting":"A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas","sponsor":"Dren Bio","started":"2022-07-13","startedType":"actual","enrolled":200,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05475925/","neighbours":{"cancer":[{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"},{"id":"t-large-granular-lymphocytic-leukaemia","kind":"cancer","name":"T-cell large granular lymphocytic leukaemia","route":"/cancers/t-large-granular-lymphocytic-leukaemia/"}],"drug":[{"id":"dr-01","kind":"drug","name":"DR-01","route":"/drugs/dr-01/"}],"company":[{"id":"dren-bio","kind":"company","name":"Dren Bio","route":"/companies/dren-bio/"}]}}